Οξανδρολόνη (Greek Wikipedia)

Analysis of information sources in references of the Wikipedia article "Οξανδρολόνη" in Greek language version.

refsWebsite

Global rank Greek rank

15nih.gov

4^th place

14doi.org

2^nd place

3^rd place

6books.google.com

3^rd place

6^th place

5fda.gov

447^th place

368^th place

2worldcat.org

5^th place

8^th place

1umich.edu

459^th place

313^th place

1drugs.com

399^th place

130^th place

1justice.gc.ca

2,540^th place

9,585^th place

1gov.uk

432^nd place

530^th place

1archive.org

6^th place

5^th place

archive.org

«Oxandrolone: a potent anabolic steroid of novel chemical configuration». The Journal of Clinical Endocrinology and Metabolism 22 (9): 921–4. September 1962. doi:10.1210/jcem-22-9-921. PMID 13894381. https://archive.org/details/sim_journal-of-clinical-endocrinology-and-metabolism_1962-09_22_9/page/921.

books.google.com

Ashraf Mozayani· Lionel Raymon (15 Οκτωβρίου 2003). Handbook of Drug Interactions: A Clinical and Forensic Guide. Springer Science & Business Media. σελίδες 513–. ISBN 978-1-59259-654-6.
R.A.S Hemat (2 Μαρτίου 2003). Andropathy. Urotext. σελίδες 108–. ISBN 978-1-903737-08-8.
William Llewellyn (2011). Anabolics. Molecular Nutrition Llc. σελίδες 342–352. ISBN 978-0-9828280-1-4.
Jeffrey K. Aronson (21 Φεβρουαρίου 2009). Meyler's Side Effects of Endocrine and Metabolic Drugs. Elsevier. σελίδες 142–. ISBN 978-0-08-093292-7.
The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. 14 Νοεμβρίου 2014. σελίδες 911–. ISBN 978-1-4757-2085-3.
Index Nominum 2000: International Drug Directory. Taylor & Francis. 2000. σελίδες 767–. ISBN 978-3-88763-075-1.

doi.org

dx.doi.org

«Oxandrolone treatment in adults with severe thermal injury». Pharmacotherapy 29 (2): 213–26. February 2009. doi:10.1592/phco.29.2.213. PMID 19170590. https://deepblue.lib.umich.edu/bitstream/2027.42/90285/1/phco.29.2.213.pdf.
«The efficacy and safety of oxandrolone treatment for patients with severe burns: A systematic review and meta-analysis». Burns 42 (4): 717–27. June 2016. doi:10.1016/j.burns.2015.08.023. PMID 26454425.
«Burns: an update on current pharmacotherapy». Expert Opinion on Pharmacotherapy 13 (17): 2485–94. December 2012. doi:10.1517/14656566.2012.738195. PMID 23121414.
«Pharmacology of anabolic steroids». British Journal of Pharmacology 154 (3): 502–21. June 2008. doi:10.1038/bjp.2008.165. PMID 18500378.
«Indications of prevalence, practice and effects of anabolic steroid use in Great Britain». International Journal of Sports Medicine 18 (7): 557–62. October 1997. doi:10.1055/s-2007-972681. PMID 9414081. «Low dose 28 +/- 18; High dose 80 +/- 13».
«Current management options for hereditary angioedema». Current Allergy and Asthma Reports 12 (4): 273–80. August 2012. doi:10.1007/s11882-012-0273-4. PMID 22729959.
«Alcoholic hepatitis: a clinician's guide». Clinics in Liver Disease 16 (2): 371–85. May 2012. doi:10.1016/j.cld.2012.03.015. PMID 22541704.
«Novel approaches to short stature therapy». Best Practice & Research. Clinical Endocrinology & Metabolism 29 (3): 353–66. June 2015. doi:10.1016/j.beem.2015.01.003. PMID 26051296.
«Safety and efficacy of oxandrolone in growth hormone-treated girls with Turner syndrome: evidence from recent studies and recommendations for use». Hormone Research in Paediatrics 81 (5): 289–97. 2014. doi:10.1159/000358195. PMID 24776783.
«Emerging medication for the treatment of male hypogonadism». Expert Opinion on Emerging Drugs 17 (2): 239–59. June 2012. doi:10.1517/14728214.2012.683411. PMID 22612692.
Moore, D.C.; Ruvalcaba, R.HA. (1991). «Late Onset Gynecomastia Associated with Oxandrolone Therapy in Adolescents with Short Stature». Journal of Pediatric Endocrinology and Metabolism 4 (4). doi:10.1515/JPEM.1991.4.4.249. ISSN 2191-0251.
«The anabolic androgenic steroid oxandrolone in the treatment of wasting and catabolic disorders: review of efficacy and safety». Drugs 64 (7): 725–50. 2004. doi:10.2165/00003495-200464070-00004. PMID 15025546.
Pappo, Raphael; Jung, Christopher J. (1962). «2-oxasteroids: A new class of biologically active compounds». Tetrahedron Letters 3 (9): 365–371. doi:10.1016/S0040-4039(00)70883-5. ISSN 0040-4039.
«Oxandrolone: a potent anabolic steroid of novel chemical configuration». The Journal of Clinical Endocrinology and Metabolism 22 (9): 921–4. September 1962. doi:10.1210/jcem-22-9-921. PMID 13894381. https://archive.org/details/sim_journal-of-clinical-endocrinology-and-metabolism_1962-09_22_9/page/921.

drugs.com

«Oxandrolone».

fda.gov

«Controlled Substances Act». United States Food and Drug Administration. 11 Ιουνίου 2009. Ανακτήθηκε στις 17 Ιουνίου 2016.
Demling, Robert H. (Σεπτεμβρίου 2004). «Oxandrolone (Oxandrin) use and the interaction with warfarin» (PDF). U.S. Food and Drug Administration. Ανακτήθηκε στις 20 Ιουνίου 2016.
Ottery, Faith D. (20 Απριλίου 2004). «Oxandrin (oxandrolone) Dear Healthcare Professional Letter Apr 2004». Safety Alerts for Human Medical Products. U.S. Food and Drug Administration. Ανακτήθηκε στις 20 Ιουνίου 2016.

accessdata.fda.gov

«Oxandrolone Tablets, USP - Rx only» (PDF). Drugs@FDA. U.S. Food and Drug Administration. 1 Δεκεμβρίου 2006. Ανακτήθηκε στις 21 Ιουνίου 2016.
«Oxandrin (oxandrolone tablets, USP)» (PDF). Drugs@FDA. BTG Pharmaceuticals, U.S. Food and Drug Administration. 21 Απριλίου 2003. Ανακτήθηκε στις 21 Ιουνίου 2016.

gov.uk

«List of most commonly encountered drugs currently controlled under the misuse of drugs legislation - GOV.UK». www.gov.uk. Ανακτήθηκε στις 14 Ιανουαρίου 2017.

justice.gc.ca

laws-lois.justice.gc.ca

Branch, Legislative Services. «Consolidated federal laws of Canada, Controlled Drugs and Substances Act». laws-lois.justice.gc.ca. Ανακτήθηκε στις 14 Ιανουαρίου 2017.

nih.gov

ncbi.nlm.nih.gov

«Oxandrolone treatment in adults with severe thermal injury». Pharmacotherapy 29 (2): 213–26. February 2009. doi:10.1592/phco.29.2.213. PMID 19170590. https://deepblue.lib.umich.edu/bitstream/2027.42/90285/1/phco.29.2.213.pdf.
«The efficacy and safety of oxandrolone treatment for patients with severe burns: A systematic review and meta-analysis». Burns 42 (4): 717–27. June 2016. doi:10.1016/j.burns.2015.08.023. PMID 26454425.
«Burns: an update on current pharmacotherapy». Expert Opinion on Pharmacotherapy 13 (17): 2485–94. December 2012. doi:10.1517/14656566.2012.738195. PMID 23121414.
«Pharmacology of anabolic steroids». British Journal of Pharmacology 154 (3): 502–21. June 2008. doi:10.1038/bjp.2008.165. PMID 18500378.
«Indications of prevalence, practice and effects of anabolic steroid use in Great Britain». International Journal of Sports Medicine 18 (7): 557–62. October 1997. doi:10.1055/s-2007-972681. PMID 9414081. «Low dose 28 +/- 18; High dose 80 +/- 13».
«Current management options for hereditary angioedema». Current Allergy and Asthma Reports 12 (4): 273–80. August 2012. doi:10.1007/s11882-012-0273-4. PMID 22729959.
«Alcoholic hepatitis: a clinician's guide». Clinics in Liver Disease 16 (2): 371–85. May 2012. doi:10.1016/j.cld.2012.03.015. PMID 22541704.
«Novel approaches to short stature therapy». Best Practice & Research. Clinical Endocrinology & Metabolism 29 (3): 353–66. June 2015. doi:10.1016/j.beem.2015.01.003. PMID 26051296.
«Safety and efficacy of oxandrolone in growth hormone-treated girls with Turner syndrome: evidence from recent studies and recommendations for use». Hormone Research in Paediatrics 81 (5): 289–97. 2014. doi:10.1159/000358195. PMID 24776783.
«Emerging medication for the treatment of male hypogonadism». Expert Opinion on Emerging Drugs 17 (2): 239–59. June 2012. doi:10.1517/14728214.2012.683411. PMID 22612692.
«The anabolic androgenic steroid oxandrolone in the treatment of wasting and catabolic disorders: review of efficacy and safety». Drugs 64 (7): 725–50. 2004. doi:10.2165/00003495-200464070-00004. PMID 15025546.
«Oxandrolone: a potent anabolic steroid of novel chemical configuration». The Journal of Clinical Endocrinology and Metabolism 22 (9): 921–4. September 1962. doi:10.1210/jcem-22-9-921. PMID 13894381. https://archive.org/details/sim_journal-of-clinical-endocrinology-and-metabolism_1962-09_22_9/page/921.

pubmedcentral.nih.gov

«Burns: an update on current pharmacotherapy». Expert Opinion on Pharmacotherapy 13 (17): 2485–94. December 2012. doi:10.1517/14656566.2012.738195. PMID 23121414.
«Pharmacology of anabolic steroids». British Journal of Pharmacology 154 (3): 502–21. June 2008. doi:10.1038/bjp.2008.165. PMID 18500378.

nlm.nih.gov

«Oxandrolone». MedlinePlus. The American Society of Health-System Pharmacists, Inc. 15 Μαΐου 2016. Ανακτήθηκε στις 21 Ιουνίου 2016.

umich.edu

deepblue.lib.umich.edu

«Oxandrolone treatment in adults with severe thermal injury». Pharmacotherapy 29 (2): 213–26. February 2009. doi:10.1592/phco.29.2.213. PMID 19170590. https://deepblue.lib.umich.edu/bitstream/2027.42/90285/1/phco.29.2.213.pdf.

worldcat.org

Moore, D.C.; Ruvalcaba, R.HA. (1991). «Late Onset Gynecomastia Associated with Oxandrolone Therapy in Adolescents with Short Stature». Journal of Pediatric Endocrinology and Metabolism 4 (4). doi:10.1515/JPEM.1991.4.4.249. ISSN 2191-0251.
Pappo, Raphael; Jung, Christopher J. (1962). «2-oxasteroids: A new class of biologically active compounds». Tetrahedron Letters 3 (9): 365–371. doi:10.1016/S0040-4039(00)70883-5. ISSN 0040-4039.